Thais Ribeiro Peclat1, Bo Shi2, John Varga2, Eduardo Nunes Chini1. 1. Signal Transduction and Molecular Nutrition Laboratory, Kogod Aging Center, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota. 2. Northwestern Scleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, USA.
Abstract
PURPOSE OF REVIEW: Here we review recent literature on the emerging role of nicotinamide adenine dinucleotide (NAD) metabolism and its dysfunction via the enzyme CD38 in the pathogenesis of rheumatologic diseases. We evaluate the potential of targeting CD38 to ameliorate NAD-related metabolic imbalance and tissue dysfunction in the treatment of systemic sclerosis (SSc), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA). RECENT FINDINGS: In this review, we will discuss emerging basic, preclinical, and human data that point to the novel role of CD38 in dysregulated NAD-homeostasis in SSc, SLE, and RA. In particular, recent studies implicate increased activity of CD38, one of the main enzymes in NAD catabolism, in the pathogenesis of persistent systemic fibrosis in SSc, and increased susceptibility of SLE patients to infections. We will also discuss recent studies that demonstrate that a cytotoxic CD38 antibody can promote clearance of plasma cells involved in the generation of RA antibodies. SUMMARY: Recent studies identify potential therapeutic approaches for boosting NAD to treat rheumatologic diseases including SSc, RA, and SLE, with particular attention to inhibition of CD38 enzymatic activity as a target. Key future directions in the field include the determination of the cell-type specificity and role of CD38 enzymatic activity versus CD38 structural roles in human diseases, as well as the indicators and potential side effects of CD38-targeted treatments.
PURPOSE OF REVIEW: Here we review recent literature on the emerging role of nicotinamide adenine dinucleotide (NAD) metabolism and its dysfunction via the enzyme CD38 in the pathogenesis of rheumatologic diseases. We evaluate the potential of targeting CD38 to ameliorate NAD-related metabolic imbalance and tissue dysfunction in the treatment of systemic sclerosis (SSc), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA). RECENT FINDINGS: In this review, we will discuss emerging basic, preclinical, and human data that point to the novel role of CD38 in dysregulated NAD-homeostasis in SSc, SLE, and RA. In particular, recent studies implicate increased activity of CD38, one of the main enzymes in NAD catabolism, in the pathogenesis of persistent systemic fibrosis in SSc, and increased susceptibility of SLE patients to infections. We will also discuss recent studies that demonstrate that a cytotoxic CD38 antibody can promote clearance of plasma cells involved in the generation of RA antibodies. SUMMARY: Recent studies identify potential therapeutic approaches for boosting NAD to treat rheumatologic diseases including SSc, RA, and SLE, with particular attention to inhibition of CD38 enzymatic activity as a target. Key future directions in the field include the determination of the cell-type specificity and role of CD38 enzymatic activity versus CD38 structural roles in human diseases, as well as the indicators and potential side effects of CD38-targeted treatments.
Authors: Pinar Aksoy; Carlos Escande; Thomas A White; Michael Thompson; Sandra Soares; Juan Claudio Benech; Eduardo N Chini Journal: Biochem Biophys Res Commun Date: 2006-08-22 Impact factor: 3.575
Authors: Juliana Camacho-Pereira; Mariana G Tarragó; Claudia C S Chini; Veronica Nin; Carlos Escande; Gina M Warner; Amrutesh S Puranik; Renee A Schoon; Joel M Reid; Antonio Galina; Eduardo N Chini Journal: Cell Metab Date: 2016-06-14 Impact factor: 27.287
Authors: Hongjun Shi; Annabelle Enriquez; Melissa Rapadas; Ella M M A Martin; Roni Wang; Julie Moreau; Chai K Lim; Justin O Szot; Eddie Ip; James N Hughes; Kotaro Sugimoto; David T Humphreys; Aideen M McInerney-Leo; Paul J Leo; Ghassan J Maghzal; Jake Halliday; Janine Smith; Alison Colley; Paul R Mark; Felicity Collins; David O Sillence; David S Winlaw; Joshua W K Ho; Gilles J Guillemin; Matthew A Brown; Kazu Kikuchi; Paul Q Thomas; Roland Stocker; Eleni Giannoulatou; Gavin Chapman; Emma L Duncan; Duncan B Sparrow; Sally L Dunwoodie Journal: N Engl J Med Date: 2017-08-10 Impact factor: 91.245
Authors: Carles Cantó; Riekelt H Houtkooper; Eija Pirinen; Dou Y Youn; Maaike H Oosterveer; Yana Cen; Pablo J Fernandez-Marcos; Hiroyasu Yamamoto; Pénélope A Andreux; Philippe Cettour-Rose; Karl Gademann; Chris Rinsch; Kristina Schoonjans; Anthony A Sauve; Johan Auwerx Journal: Cell Metab Date: 2012-06-06 Impact factor: 27.287
Authors: Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini Journal: Am J Physiol Cell Physiol Date: 2022-02-09 Impact factor: 4.249
Authors: Bo Shi; Wenxia Wang; Benjamin Korman; Li Kai; Qianqian Wang; Jun Wei; Swarna Bale; Roberta Goncalves Marangoni; Swati Bhattacharyya; Stephen Miller; Dan Xu; Mahzad Akbarpour; Paul Cheresh; Daniele Proccissi; Demirkan Gursel; Jair Machado Espindola-Netto; Claudia C S Chini; Guilherme C de Oliveira; Johann E Gudjonsson; Eduardo N Chini; John Varga Journal: iScience Date: 2020-12-07